Compare Stocks

Date Range: 

 Aclaris TherapeuticsAntibe TherapeuticsAntibe TherapeuticsSupernus PharmaceuticalsPMV Pharmaceuticals
SymbolNASDAQ:ACRSNASDAQ:ATBPDOTCMKTS:ATBPDNASDAQ:SUPNNASDAQ:PMVP
Price Information
Current Price$22.95$3.64$3.64$29.37$35.00
52 Week RangeBuyN/AN/ABuyBuy
MarketRank™
Overall Score0.80.10.11.91.2
Analysis Score0.00.00.03.51.4
Community Score2.60.00.03.02.9
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.01.71.7
Earnings & Valuation Score0.60.60.61.30.0
Analyst Ratings
Consensus RecommendationBuyN/AN/ABuyBuy
Consensus Price TargetN/AN/AN/A$37.50$38.00
% Upside from Price TargetN/AN/AN/A27.68% upside8.57% upside
Trade Information
Market Cap$1.20 billion$1.41 billion$1.41 billion$1.56 billion$1.57 billion
Beta1.20.570.571.38N/A
Average Volume2,286,86229,71029,710580,509154,050
Sales & Book Value
Annual Revenue$4.23 million$7.51 million$7.51 million$392.76 millionN/A
Price / Sales282.59187.57187.573.96N/A
CashflowN/AN/AN/A$2.60 per shareN/A
Price / CashN/AN/AN/A11.30N/A
Book Value$1.69 per share$0.10 per share$0.10 per share$11.35 per shareN/A
Price / Book13.5836.4036.402.59N/A
Profitability
Net Income$-161,350,000.00$-14,540,000.00$-14,540,000.00$113.06 millionN/A
EPS($2.25)($0.50)($0.50)$2.10N/A
Trailing P/E RatioN/AN/AN/A12.190.00
Forward P/E RatioN/AN/AN/A18.59N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-941.07%-273.96%-273.96%27.09%N/A
Return on Equity (ROE)-104.00%-176.23%-150.49%20.02%N/A
Return on Assets (ROA)-64.47%-106.91%-98.51%9.67%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.26%N/AN/A0.53%N/A
Current Ratio4.54%6.55%5.97%1.84%N/A
Quick Ratio4.54%5.95%5.42%1.70%N/A
Ownership Information
Institutional Ownership Percentage59.10%N/AN/A96.11%69.72%
Insider Ownership Percentage8.20%N/AN/A6.57%N/A
Miscellaneous
Employees57474756344
Shares Outstanding52.09 million387.00 million387.00 million53.02 million44.93 million
Next Earnings Date8/6/2021 (Estimated)N/AN/A8/17/2021 (Estimated)6/2/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CFO Winston Kung Sells 4,500 SharesPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CFO Winston Kung Sells 4,500 Shares
americanbankingnews.com - May 5 at 4:34 AM
Were Interested To See How PMV Pharmaceuticals (NASDAQ:PMVP) Uses Its Cash Hoard To GrowWe're Interested To See How PMV Pharmaceuticals (NASDAQ:PMVP) Uses Its Cash Hoard To Grow
nasdaq.com - May 2 at 2:24 PM
PMV Pharmaceuticals (NASDAQ:PMVP) Sees Unusually-High Trading VolumePMV Pharmaceuticals (NASDAQ:PMVP) Sees Unusually-High Trading Volume
americanbankingnews.com - April 28 at 12:38 PM
PMV Pharmaceuticals (NASDAQ:PMVP) Trading Down 4.7%PMV Pharmaceuticals (NASDAQ:PMVP) Trading Down 4.7%
americanbankingnews.com - April 27 at 11:58 AM
PMV Pharmaceuticals (NASDAQ:PMVP) Sees Strong Trading VolumePMV Pharmaceuticals (NASDAQ:PMVP) Sees Strong Trading Volume
americanbankingnews.com - April 22 at 11:59 AM
PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Up to $31.26PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Up to $31.26
americanbankingnews.com - April 21 at 12:54 PM
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of DirectorsAbeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
benzinga.com - April 19 at 7:35 AM
PMV Pharmaceuticals (NASDAQ:PMVP) Sees Large Volume IncreasePMV Pharmaceuticals (NASDAQ:PMVP) Sees Large Volume Increase
americanbankingnews.com - April 15 at 11:40 AM
Pmv Pharmaceuticals Inc (PMVP)Pmv Pharmaceuticals Inc (PMVP)
investing.com - April 12 at 12:40 AM
PMV Pharma Presents Late-Breaking Preclinical...PMV Pharma Presents Late-Breaking Preclinical...
benzinga.com - April 10 at 6:16 PM
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the ...PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the ...
apnews.com - April 10 at 6:16 PM
PMV Pharmaceuticals Inc. [PMVP] is -46.33% lower this YTD. Is it still time to buy?PMV Pharmaceuticals Inc. [PMVP] is -46.33% lower this YTD. Is it still time to buy?
dbtnews.com - March 25 at 11:09 PM
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Down Almost -10.23% in 1 Month, But Long Term Looking GoodPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Down Almost -10.23% in 1 Month, But Long Term Looking Good
marketingsentinel.com - March 25 at 1:07 PM
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American ...PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American ...
apnews.com - March 11 at 7:59 AM
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate ...PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate ...
apnews.com - March 4 at 3:38 AM
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Nasdaq:PMVPPMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Nasdaq:PMVP
compsmag.com - March 3 at 10:37 PM
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate HighlightsPMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
finance.yahoo.com - March 3 at 5:35 PM
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory BoardPMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
finance.yahoo.com - February 16 at 9:14 AM
Were Not Worried About PMV Pharmaceuticals (NASDAQ:PMVP) Cash BurnWe're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn
finance.yahoo.com - December 25 at 3:10 PM
Is PMVP A Good Stock To Buy Now?Is PMVP A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 7:39 PM
PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx ConferencePMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 24 at 7:14 PM
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
finance.yahoo.com - November 23 at 12:59 PM
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate HighlightsPMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
finance.yahoo.com - November 13 at 8:55 AM
PMV Pharmaceuticals Inc.PMV Pharmaceuticals Inc.
barrons.com - November 1 at 12:37 PM
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C MutationPMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
finance.yahoo.com - October 24 at 12:42 AM
DateCompanyBrokerageAction
4/27/2021Aclaris TherapeuticsHC WainwrightInitiated Coverage
1/2/2020Aclaris TherapeuticsSVB LeerinkReiterated Rating
10/11/2019Aclaris TherapeuticsWilliam BlairReiterated Rating
9/6/2019Aclaris TherapeuticsJMP SecuritiesDowngrade
8/9/2019Aclaris TherapeuticsCantor FitzgeraldReiterated Rating
4/19/2021Supernus PharmaceuticalsJefferies Financial GroupUpgrade
2/3/2021Supernus PharmaceuticalsPiper SandlerBoost Price Target
4/16/2020Supernus PharmaceuticalsStifel NicolausLower Price Target
11/8/2019Supernus PharmaceuticalsBerenberg BankDowngrade
8/7/2019Supernus PharmaceuticalsCowenSet Price Target
8/7/2019Supernus PharmaceuticalsMizuhoReiterated Rating
3/4/2019Supernus PharmaceuticalsB. RileySet Price Target
1/16/2019Supernus PharmaceuticalsPiper Jaffray CompaniesSet Price Target
10/20/2020PMV PharmaceuticalsEvercore ISIInitiated Coverage
10/20/2020PMV PharmaceuticalsBank of AmericaInitiated Coverage
10/20/2020PMV PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.